The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based study - Takeaways - MDSpire

The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based study

  • By

  • Bregje Mol

  • Kim van Munster

  • Rinse Weersma

  • Akin Inderson

  • Kirsten Boonstra

  • Joost Drenth

  • Suzanne van Meer

  • Elsemieke de Vries

  • Marcel Spanier

  • Anton Vrij

  • Tessa Verlaan

  • Femke van Duijn

  • Willemijn Ponsioen

  • Marcel Dijkgraaf

  • Cyriel Ponsioen

  • June 15, 2026

  • 0 min

Share

  • 1

    Primary sclerosing cholangitis (PSC) affects 6–32 individuals per 100,000 and is linked to increased risk of hepatobiliary malignancies and colorectal cancer.

  • 2

    Ursodeoxycholic acid (UDCA) is the only drug used for PSC, but clinical research has not demonstrated its efficacy in improving transplant-free survival.

  • 3

    The EpiPSC2 study is a population-based registry in the Netherlands that collects long-term data on PSC patients to evaluate treatment effects.

  • 4

    Data on UDCA use were meticulously collected through multiple sources, ensuring accurate assessment of its impact on PSC progression.

  • 5

    The study aims to assess UDCA's effectiveness on transplant-free survival in PSC patients, addressing the limitations of previous research.

Original Source(s)

The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based study

  • by Bregje Mol, Kim van Munster, Rinse Weersma, Akin Inderson, Kirsten Boonstra, Joost Drenth, Suzanne van Meer, Elsemieke de Vries, Marcel Spanier, Anton Vrij, Tessa Verlaan, Femke van Duijn, Willemijn Ponsioen, Marcel Dijkgraaf, Cyriel Ponsioen

  • June 15, 2026

Related Content

Correction: Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation

Cross-species systems analysis distinguishes inflammatory remodeling from primary mucus secretory failure in inflammatory bowel disease

Integrated single-cell and spatial transcriptomics reveal immune landscape and NKT–Th1 signatures in colorectal cancer